Bipartisan Bill Introduced to Encourage Generic Drug Use in Medicaid - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Bipartisan Bill Introduced to Encourage Generic Drug Use in Medicaid


ePT--the Electronic Newsletter of Pharmaceutical Technology

A bill introduced by Senators Scott Brown (R-MA), Ron Wyden (D-OR), and John McCain (R-AZ) on July 13, 2011, aims to encourage states to reduce Medicaid spending by offering financial incentives to substitute generic drugs for branded ones where possible. The bill, called the Affordable Medicines Utilization Act of 2011, encourages generic-drug substitution under Medicaid by allowing states to keep a portion of the savings they realize.

A report issued by the American Enterprise Institute for Public Policy Research estimates that states overspent by more than $3 million by not using generic drugs where available. The report predicts that savings from generic drugs will increase in 2011–2012 when other widely used drugs lose patent protection. Brown, in a press release, called the bill “common sense.” In the same press release, McCain added, “This bipartisan proposal incentivizes state Medicaid programs to substitute generics for more expensive brand-name drugs, introducing real competition for reimbursement dollars and saving taxpayers’ hard-earned money.”

Supporters of generic drugs came out in favor of the bill. Bob Billings, executive director of the Generic Pharmaceutical Association, said in a press release, “This legislation is exactly the kind of solution those in Washington should look to when searching for ways to rein in our country’s health care spending.”

Teva Pharmaceuticals also expressed its support for the measure. “As the largest provider of generic pharmaceuticals in the United States, Teva has been and continues to be committed to providing patients with access to the life-saving medicines they need,” the company said in a press release. “This legislation will encourage states to increase access to high-quality, low-cost pharmaceuticals for their Medicaid populations. At a time when state government officials are struggling to close their budget shortfalls, improving access to FDA approved generic medicines will help lower their healthcare costs while maintaining access to care.”

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
33%
Breakthrough designations
11%
Protecting the supply chain
39%
Expedited reviews of drug submissions
11%
More stakeholder involvement
6%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here